ArticleJournal of population research (Canberra, A.C.T.)2022
Loss of life expectancy due to respiratory infectious diseases: findings from the global burden of disease study in 195 countries and territories 1990-2017.
Article in Journal of population research (Canberra, A.C.T.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- An umbrella review of the diagnostic value of next-generation sequencing in infectious diseases.International journal of clinical pharmacy · 2024Pooled it
- Role-specific household contact patterns in urban and rural China: Implications for influenza household transmission.Infectious Disease Modelling · 2027Article
- SWORD survey: Seasonal trends in hospitalisation and mortality among patients with respiratory illnesses in India.Lung India : official organ of Indian Chest Society · 2026Article
- Temporal Trends in Lower Respiratory Infection Mortality in Ecuador, 2012-2022.Tropical medicine and infectious disease · 2026Article
- Multicenter clinical performance and comparative evaluation of the LIAISON PLEX RespiratoryJournal of clinical microbiology · 2025Article
- A Phase II, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of HEX17, a Novel Broad-Spectrum Antiviral Drug, in a Controlled Human Infection Model of Influenza Challenge.Infectious diseases and therapy · 2025Article
- Comparison of Two Field Deployable PCR Platforms for SARS-CoV-2 and Influenza A and B Viruses' Detection.Pathogens (Basel, Switzerland) · 2025Article
- Artificial intelligence in epidemic watch: revolutionizing infectious diseases surveillance.Frontiers in digital health · 2025Review
- A human behavior-based model for respiratory infectious diseases prediction.Frontiers in public health · 2025Article
- Article
- Global epidemiological trends in the incidence and deaths of acute respiratory infections from 1990 to 2021.Heliyon · 2024Article
- Guidelines for Antibiotics Prescription in Critically Ill Patients.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024Article
- Elderly patients with tuberculosis in a low-incidence country - Clinical characteristics, inflammation and outcome.The Journal of infection · 2024Article
- Clinical application of nanopore-targeted sequencing technology in bronchoalveolar lavage fluid from patients with pulmonary infections.Microbiology spectrum · 2024Article
- Recommendations on Rapid Diagnostic Point-of-care Molecular Tests for Respiratory Infections in the United Arab Emirates.The open respiratory medicine journal · 2024Review
- Antimicrobial resistance expansion in pathogens: a review of current mitigation strategies and advances towards innovative therapy.JAC-antimicrobial resistance · 2023Review
- Disparity in spectrum of infectious diseases between in-school and out-of-school children, adolescents, and youths in China: findings from a successive national surveillance from 2013 to 2021.The Lancet regional health. Western Pacific · 2023Article
- Influences of obstacle factors on the transmission trends of respiratory infectious diseases in indoor public places.Journal of building engineering · 2023Article
- Respiratory Tract Infections and Laboratory Diagnostic Methods: A Review with A Focus on Syndromic Panel-Based Assays.Microorganisms · 2022Review
- Forecasting the transmission trends of respiratory infectious diseases with an exposure-risk-based model at the microscopic level.Environmental research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding of the patterns of and changes in mortality from respiratory infectious diseases (RID) and its contribution to loss of life expectancy (LE) is inadequate in the existing literature. With rapid sociodemographic changes globally, and the current COVID-19 pandemic, it is timely to revisit the disease burden of RID. Using the approaches of life table and cause-eliminated life table based on data from the Global Burden of Disease Study (GBD), the study analyses loss of LE due to RID in 195 countries/territories and its changes during the period 1990-2017. Results indicate that loss of LE due to RID stood at 1.29 years globally in 2017 globally and varied widely by age, gender, and geographic location, with men, elderly people, and populations in middle/low income countries/territories suffering a disproportionately high loss of LE due to RID. Additionally, loss of LE due to RID decreased remarkably by 0.97 years globally during the period 1990-2017 but increased slightly among populations older than 70 years and in many high income countries/territories. Results suggest that RID still pose a severe threat for population and public health, and that amid dramatic sociodemographic changes globally, the disease burden of RID may resurge. The study presents the first examination of the life-shortening effect of RID at the global and country/territory levels, providing new understanding of the changing disease burden of RID and shedding light on the potential consequences of the current COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.